DeLLphi-301 is a clinical study that is testing an investigational drug called tarlatamab. The study is being done to see how safe and effective tarlatamab is at treating patients with small cell lung cancer (SCLC) who have already had two or more previous treatments.
Underlined terms can be clicked for definition.
Tarlatamab is designed to help the body’s immune cells find, attach to, and attack cancer cells.
Patients who are 18 years or older
Diagnosed with small cell lung cancer (SCLC) confirmed by tissue biopsy
Whose cancer has returned or is not responding to treatment after trying two or more previous treatments
With tumor(s) that can be seen on imaging
Study participants must also meet additional eligibility criteria.
Where can I get more information?
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
Step 1: Screening
At your first study visit(s), you will:
*This may not be needed in all cases. The study doctor will let you know if this is not needed.
If you meet the requirements and decide to join the study, you will move on to Step 2.
Step 2: Treatment with tarlatamab (study drug)
At each treatment visit, all study participants will receive tarlatamab (study drug) by infusion (in a vein).
The study will be done in two parts:
During this time, you will:
* As a precaution, you will need to stay in the hospital for at least 48 hours after your first two tarlatamab treatments to monitor your health status. For your next two doses, you may need to stay in the hospital if you have side effects from the study drug during your prior treatments.
Step 3: End of treatment
You will continue to receive tarlatamab in the study based on the results of your bloodwork and imaging. Your study treatment may stop if any of the following happen:
The study team will schedule a follow-up visit with you approximately 6 weeks after your last dose of tarlatamab.
*You may stay on the study drug if you are eligible and if the study sponsor and study doctor agree it is still helping you.
Step 4: Long term follow-up (~3 to 5 years)
The study team may follow-up with you by phone or ask you visit the clinic approximately once every 3 months.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical study or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
